This project is the first in a planned series of studies to develop and validate a brain imaging biomarker of
cardioembolic stroke toward the long term goal of identifying a high risk group that may preferentially benefit
from long term cardiac monitoring or anticoagulation in the absence of proven cardioembolic source.
The primary hypothesis of this study is to test whether the occurrence spatially separate acute ischemic
strokes located within multiple vascular territories (MVT) supplying the brain (right carotid, left carotid, or
posterior circulation) on DWI within 48 hours from stroke onset is associated with proven cardioembolic source.
Subsequent studies will attempt to validate the MVT biomarker in three separate samples: patients undergoing long-term cardiac monitoring with an implantable cardiac monitor, patients with new lesions on repeat MRI 3-6 months from onset, and subjects with embolic stroke of unknown source (ESUS) in ongoing prevention trials of anti-platelets vs anticoagulants.
It is anticipated that approximately 63% of ischemic stroke diagnoses from Lone Star Stroke Consortium (LSS) hubs will be eligible for this retrospective analysis. Approximately 32% of the ischemic stroke diagnoses from LSS spoke sites will be eligible.